



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Donald R. Steinberg
Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, MA 02109

In Re: Patent Term Extension
Application for
U.S. Patent No. 5,196,404

Dear Mr. Steinberg :

MAR 18 2010

Pursuant to the Order of United States District Court for the Eastern District of Virginia, Alexandria Division, in The Medicines Company v. David Kappos et al., civil action no. 01:10-cv-81, the USPTO is issuing an interim extension under the provision of § 156(e)(2) for a period of 60 days.

While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website: <http://www.fda.gov/opacom/morechoices/fdaforms/default.html> (<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail at mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Associate Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: Angiomax
FDA Docket No.: 01E-0213

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE


In re Biogen Idec MA Inc. :
Request for Patent Term Extension : ORDER GRANTING
U.S. Patent No. 5,196,404 : INTERIM EXTENSION

Biogen Idec MA Inc., the owner of record in the United States Patent and Trademark Office (USPTO) of U.S. Patent No. 5,196,404 (the '404 patent), through its authorized agent, The Medicines Company, filed an application for patent term extension under 35 U.S.C. § 156 on February 14, 2001. The original term of the patent is due to expire on March 23, 2010. The patent claims the active ingredient bivalirudin, in the human drug product Angiomax®, which was approved by the Food and Drug Administration for commercial marketing or use on December 15, 2000. An extension of 1,728 days is requested.

Pursuant to the Memorandum Opinion of United States District Court for the Eastern District of Virginia, Alexandria Division, in The Medicines Company v. David Kappos et al., civil action no. 01:10-cv-81, the USPTO is issuing an interim extension under the provision of § 156(e)(2).

An interim extension under 35 U.S.C. § 156(e)(2) of the term of U.S. Patent No. 5,196,404 is granted for a period of 60 days from the original expiration date of the patent, to and including, May 23, 2010.

3/15/2010
Date



David J. Kappos
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office